Perspective Therapeutics (CATX) Income from Non-Controlling Interests (2016 - 2023)
Perspective Therapeutics (CATX) reported Income from Non-Controlling Interests of $15000.0 for Q2 2023, down 68.75% sequentially from $48000.0 in Q4 2016.
Perspective Therapeutics (CATX) Income from Non-Controlling Interests (2016 - 2023) Analysis & Trends
Perspective Therapeutics (CATX) has 2 years of Income from Non-Controlling Interests data on file, last reported at $15000.0 in Q2 2023.
- For the quarter ending Q2 2023, Income from Non-Controlling Interests changed N/A year-over-year to $15000.0; the trailing twelve-month figure through Sep 2024 stood at $15000.0 (changed 0.0% YoY), and the FY2017 full-year result was $48000.0, down 89.47% from the prior year.
- Income from Non-Controlling Interests slipped to $15000.0 in Q2 2023, from $48000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $15000.0 in Q2 2023 to a low of $15000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -5.85 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 22.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 15,000.00 |
| Dec 31, 2016 | 48,000.00 |
| Jun 30, 2016 | 456,000.00 |